$INBS fiscal Q2 & 6 month financial results & highlights: - Gross profit increase of 32.6% & 11-point gross profit margin increase - Submitted FDA 510(k) & remain on track for planned expansion - Added strategic partnerships - Secured 19 accounts during Q2

$INBS reports 2024 growth and unveils its 2025 U.S. expansion strategy in its shareholder newsletter. Harry Simeonidis, President and CEO, highlights milestones already achieved and the path to entering the multi-billion-dollar U.S. #drugscreening market.

$INBS expands in the UK as Avon Freight Group adopts its Drug Testing Solution for random drug testing. With the UK drug testing market set to reach $453M by 2030, INBS is strengthening its market presence with its growing number of 400+ accounts.

$INBS announces preliminary unaudited fiscal 2025 Q2 & 6 month results: - Gross profit expected to surge by 32.6% - Higher-margin cartridge sales driving profitability & growth - US & global market expansion with FDA submission & strategic partnerships

$INBS announces plans for a major multilingual upgrade to its Intelligent Fingerprinting Drug Screening System, making it accessible to over 4 billion users worldwide. The update aligns with its global expansion goals and planned entry into the US market.

$INBS adds Quantum TM, a leading UK traffic management provider, to its client portfolio of 400+ accounts across the globe utilizing the Intelligent Fingerprint #DrugTesting Solution, as the Company anticipates entry into the US market in 2025.

$INBS partners with IVY Diagnostics to expand the adoption of its Intelligent Fingerprinting #DrugTesting Solution across Europe’s $3.6 billion drug screening market and in Middle Eastern regions.

$INBS partners with @Princebuild, a leading construction firm, to transition from saliva testing to fingerprint sweat-based drug screening across its seven UK sites.

INBS has submitted its 510(k) package to the FDA, including comprehensive performance data & validation studies. Submission is a crucial step toward planned US market entry in 2025. US entry will support revenue growth, market acquisition & partnerships.

INBS' President & CEO Harry Simeonidis and CFO Spiro Sakiris will be discussing the company's recent clinical study results & path to FDA 510(k) submission in an upcoming virtual fireside chat on Wednesday, 11 December at 4:30 p.m. ET. Registration Link:

INBS' Drug Screening System has demonstrated 94.1% accuracy in method comparison study, following recent positive PK study results. INBS will include data from PK study & method comparison study in 510(k) submission, expected in calendar Q4 of 2024.

$INBS' PK study data shows that fingerprint sweat mimics the rate and extent of codeine in blood and saliva and provides a reliable sample matrix for drug detection with quantitative data closely aligning to blood and oral fluid. Watch the video:

$INBS announces positive results of PK Study, a key milestone on the path to FDA 510(k) submission. Data from the PK study demonstrates that fingerprint sweat provides reliable sample for drug detection. #NASDAQ #FDA #MedicalTechnology

$INBS fiscal Q1 financial results & highlights: - 10% increase YoY & 20% QoQ - Cartridges surpass readers as key driver - In-clinic studies completed for FDA 510(k) - Initial PK results show strong alignment to blood & oral fluid - Saudi Arabia expansion

$INBS Partners with B2i Digital, a business-to-investor marketing firm, to amplify investor outreach by raising awareness of INBS’ patented drug screening technology, which offers a fast, non-invasive, and efficient alternative to traditional drug tests.

$INBS announces preliminary unaudited fiscal 2025 Q1 results: - expected 10% YoY & 20% QoQ revenue increase - higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary driver - expanded distribution network in Saudi Arabia

Mount Anvil celebrates 1 year of enhanced workplace safety with $INBS, purchasing 5 readers and 1750 cartridges for on-site testing within 12 months.

$INBS is scheduled to present at @theLDMicro Invitational XVII Investor Conference at 10 AM PT on October 30 in LA. Webcast:

Global engineering leader @pyrotekinc, has adopted $INBS' fingerprint drug screening solution across its Australian branches. The move to fingerprint testing will minimize operational downtime & ensure efficient, cost-effective testing of its workforce.

$INBS partners with Australian Indigenous-owned consulting agency Spirit Group to distribute the Intelligent Fingerprinting Drug Testing Solution to government and corporate clients across various industries, including mining, transportation & construction